CD4 and neoplasm: Analysis of the immune cells at the tumor site and in peripheral blood 30 days post injection, revealed that IRF7 silencing caused an increase in Gr1+CD11b+ cells and a decrease in CD4+, CD8+ T and B lymphocytes in both models (Fig. 5c–h).